Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs
In the phase 2 RIGHT Choice study, first-line ribociclib, combined with either letrozole or anastrozole plus goserelin, was associated with a doubling of progression-free survival.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

anastrozole
Title: anastrozoleCategory: MedicationsCreated: 8/5/2022 12:00:00 AMLast Editorial Review: 8/5/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 5, 2022 Category: Cancer & Oncology Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Five - Year Extended Hormone Therapy No Better in Breast Cancer
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone - receptor - positive breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 29, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Bone density loss from Anastrozole partially reverses after treatment stops
(Queen Mary University of London) A study by researchers from Queen Mary University of London shows that bone loss known to be associated with the use of the breast cancer prevention drug Anastrozole partially reverses, particularly at the lumbar spine, after stopping treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Phase I/II Trial To Evaluate Dual HER2 Combination Therapy in HR+, HER2+ Breast Cancer
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Anastrozole Extends Breast Cancer Protection Once Stopped Anastrozole Extends Breast Cancer Protection Once Stopped
A 5-year regimen of anastrozole protects women against new breast cancers for at least another 5 years they stop taking the drug.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
Breast cancer risk significantly lower at median follow - up of 131 months; effect continued after treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pharmacy, Conference News, Source Type: news

SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
TUESDAY, Dec. 17, 2019 -- Anastrozole is associated with a long-term reduction in breast cancer risk, even after treatment, according to a study published online Dec. 12 in The Lancet to coincide with the annual San Antonio Breast Cancer Symposium,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Drug that halves a woman's risk of breast cancer works for SEVEN YEARS after they stop taking it
Arimidex halves the risk of breast cancer in postmenopausal women. Now, a study at Queen Mary University of London shows these effects last for a further seven years. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2019 Category: Consumer Health News Source Type: news

Drug that prevents half of breast cancers carries on working
Anastrozole is available already, but doctors say substantially more women should be taking it. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 12, 2019 Category: Consumer Health News Source Type: news